{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:55:41Z","timestamp":1776354941024,"version":"3.51.2"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Modifying glucagon-like peptide-1 receptor (GLP-1R)\u2013targeted PET agent to achieve faster renal clearance and preserved high affinity to GLP-1R is clinically relevant. The aim of this study is to assess the performance of a newly developed GLP-1R\u2013targeted agent, <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 in localizing insulinoma, and its biodistribution, as compared with previously introduced <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Nineteen patients with endogenous hyperinsulinemic hypoglycemia were enrolled and referred for <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 PET\/CT and <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4 PET\/CT within 2 consecutive days. Diagnostic performance of the 2 tracers in localizing insulinoma was evaluated, and SUV of the lesion, normal pancreas background, kidneys, and bladder were measured.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 and <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4 PET\/CT exhibited an equivalent efficacy in detection rate (both sensitivity of 100%). Although SUV<jats:sub>max<\/jats:sub> of the tumor in <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 was significantly lower than that in <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4 (20.01 \u00b1 9.41 vs 31.78 \u00b1 15.46, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) at 50 minutes postinjection, there was no significant difference in the tumor-to-background ratio between the 2 agents (8.61 \u00b1 3.57 vs 8.18 \u00b1 3.38, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.326), and the lesions could be visible as early as 4 minutes postinjection for both agents in patients who underwent dynamic PET\/CT. In addition, <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 exhibited approximately 30% decrease of the renal accumulation compared with <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4 (SUV<jats:sub>mean<\/jats:sub>, 42.21 \u00b1 5.79 vs 58.58 \u00b1 10.06 at 50 minutes, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 is an effective agent for localizing insulinoma showing similar detectability and tumor-to-background ratio compared with <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4. Notably, <jats:sup>68<\/jats:sup>Ga-HBED-CC-exendin-4 exhibits significantly lower renal uptake than <jats:sup>68<\/jats:sup>Ga-NOTA-exendin-4, which might potentially benefit the detection of the tumors adjacent to the left kidneys.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005533","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:00:45Z","timestamp":1730815245000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Glucagon-Like Peptide-1 Receptor\u2013Targeted PET\/CT With 68Ga-HBED-CC-Exendin-4 in Localizing Insulinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Linlin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingci","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-2441","authenticated-orcid":false,"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Hong","sequence":"additional","affiliation":[{"name":"College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Jin","sequence":"additional","affiliation":[{"name":"College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-8049","authenticated-orcid":false,"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8531","authenticated-orcid":false,"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-1136","authenticated-orcid":false,"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"bib1-20241203","doi-asserted-by":"crossref","first-page":"897","DOI":"10.5306\/wjco.v12.i10.897","article-title":"Current update on imaging for pancreatic neuroendocrine neoplasms","volume":"12","year":"2021","journal-title":"World J Clin Oncol"},{"key":"bib2-20241203","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.2967\/jnumed.120.246009","article-title":"Glucagon-like peptide-1 receptor as emerging target: will it make it to the clinic?","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib3-20241203","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00003495-200767060-00008","article-title":"Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and\/or a sulfonylurea)","volume":"67","year":"2007","journal-title":"Drugs"},{"key":"bib4-20241203","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2013-3541","article-title":"Detection of metastatic insulinoma by positron emission tomography with [68Ga]exendin-4\u2014a case report","volume":"99","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"bib5-20241203","doi-asserted-by":"crossref","first-page":"e0160714","DOI":"10.1371\/journal.pone.0160714","article-title":"99mTc labeled glucagon-like peptide-1-analogue (99mTc-GLP1) scintigraphy in the management of patients with occult insulinoma","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"bib6-20241203","doi-asserted-by":"crossref","first-page":"A614","DOI":"10.1210\/jendso\/bvab048.1252","article-title":"The role of glucagon-like peptide 1 receptor PET\/CT with Ga-68-NODAGA-exendin in localising an insulinoma: lessons from a clinical case","volume":"5","year":"2021","journal-title":"J Endocr Soc"},{"key":"bib7-20241203","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3 T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20241203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cpet.2020.12.008","article-title":"Imaging of Insulinoma by targeting glucagonlike peptide-1 receptor","volume":"16","year":"2021","journal-title":"PET Clinics"},{"key":"bib9-20241203","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1210\/jc.2009-1082","article-title":"Glucagon-like peptide-1 receptor imaging for localization of insulinomas","volume":"94","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"bib10-20241203","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2967\/jnumed.115.167445","article-title":"Glucagon-like peptide-1 receptor PET\/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib11-20241203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/JP9.0000000000000053","article-title":"Decreased 68Ga-NOTA-exendin-4 renal uptake in patients pretreated with Gelofusine infusion: a randomized controlled study","volume":"3","year":"2020","journal-title":"J Pancreatol"},{"key":"bib12-20241203","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2044.2005.04529.x","article-title":"Anaphylaxis to Gelofusine confirmed by in vitro basophil activation test: a case series","volume":"61","year":"2006","journal-title":"Anaesthesia"},{"key":"bib13-20241203","first-page":"87","article-title":"68Ga-labelled-exendin-4: new GLP1R targeting agents for imaging pancreatic beta-cell and insulinoma","volume":"102\u2013103","year":"2021","journal-title":"Nucl Med Biol"},{"key":"bib14-20241203","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.regpep.2006.07.005","article-title":"A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents","volume":"137","year":"2006","journal-title":"Regul Pept"},{"key":"bib15-20241203","first-page":"74","article-title":"Oxotechnetium(V) bis(dicyanoethylenediselenolate)\u2014the first technetium complex with TcOSe4 coordination","volume":"24","year":"1984","journal-title":"Zeitschrift fur Chemie"},{"key":"bib16-20241203","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bpg.2005.05.008","article-title":"Insulinoma","volume":"19","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"bib17-20241203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13037-015-0064-7","article-title":"Preoperative glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases","volume":"9","year":"2015","journal-title":"Patient Saf Surg"},{"key":"bib18-20241203","first-page":"310","article-title":"68Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib19-20241203","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/imj.15141","article-title":"Utility of 68Ga-DOTA-exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia","volume":"51","year":"2021","journal-title":"Intern Med J"},{"key":"bib20-20241203","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12020-015-0633-7","article-title":"Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET\/CT","volume":"50","year":"2015","journal-title":"Endocrine"},{"key":"bib21-20241203","first-page":"100","article-title":"111In-exendin SPECT imaging suggests presence of residual beta cells in patients with longstanding type 1 diabetes","volume":"60","year":"2021","journal-title":"Nuklearmedizin"},{"key":"bib22-20241203","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00125-014-3166-3","article-title":"Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin","volume":"57","year":"2014","journal-title":"Diabetologia"},{"key":"bib23-20241203","first-page":"794","article-title":"Glucagonlike peptide-1 receptor imaging in individuals with type 2 diabetes","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib24-20241203","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMc1004547","article-title":"GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle","volume":"363","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:00:33Z","timestamp":1733266833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005533"}},"subtitle":["A Head-to-Head Comparison to 68Ga-NOTA-Exendin-4"],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005533","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}